Younossi, Zobair M.

The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials

Sanyal, A. J., Harrison, S. A., Ratziu, V., Abdelmalek, M. F., Diehl, A. M., Caldwell, S., Shiffman, M. L., Aguilar Schall, R., Jia, C., McColgan, B., et al. (2019) · Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 390

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis

Harrison, S. A., Abdelmalek, M. F., Caldwell, S., Shiffman, M. L., Diehl, A. M., Ghalib, R., Lawitz, E. J., Rockey, D. C., Schall, R. A., Jia, C., et al. (2018) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 384

Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality

Younossi, Z., & Henry, L. (2016) · Gastroenterology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 334

Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease

Younossi, Z. M., Paik, J. M., Stepanova, M., Ong, J., Alqahtani, S., & Henry, L. (2024) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 321

Lifestyle interventions in nonalcoholic fatty liver disease

Younossi, Z. M., Zelber-Sagi, S., Henry, L., & Gerber, L. H. (2023) · Nature Reviews Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentObesity, Physical Activity, Diet

Cited by 281

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials

Anstee, Q. M., Lawitz, E. J., Alkhouri, N., Wong, V. W., Romero‐Gomez, M., Okanoue, T., Trauner, M., Kersey, K., Li, G., Han, L., et al. (2019) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 277

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)

Golabi, P., Otgonsuren, M., de Avila, L., Sayiner, M., Rafiq, N., & Younossi, Z. M. (2018) · Medicine

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 221

Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis

Younossi, Z. M., Zelber-Sagi, S., Lazarus, J. V., Wong, V. W.-S., Yilmaz, Y., Duseja, A., Eguchi, Y., Castera, L., Pessoa, M. G., Oliveira, C. P., et al. (2025) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 194

Fatigue and Health-Related Quality of Life (HRQL) in Chronic Hepatitis C Virus Infection

Kallman, J., O’Neil, M. M., Larive, B., Boparai, N., Calabrese, L., & Younossi, Z. M. (2007) · Digestive Diseases and Sciences

Hepatitis C virus researchLiver Disease Diagnosis and Treatment

Cited by 181

Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease

Younossi, Z. M., Stepanova, M., Ong, J., Yilmaz, Y., Duseja, A., Eguchi, Y., El Kassas, M., Castellanos-Fernandez, M., George, J., Jacobson, I. M., et al. (2019) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 172

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis

Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Abdelmalek, M. F., Ding, D., Han, L., Jia, C., Huss, R. S., Chung, C., et al. (2022) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 171

Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study

Rinella, M. E., Dufour, J.-F., Anstee, Q. M., Goodman, Z., Younossi, Z., Harrison, S. A., Loomba, R., Sanyal, A. J., Bonacci, M., Trylesinski, A., et al. (2022) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 164

Introduction and Methodology: Standards of Care in Diabetes—2025

American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Callaghan, B. C., et al. (2025) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 155

Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C

Weinstein, A. A., Kallman Price, J., Stepanova, M., Poms, L. W., Fang, Y., Moon, J., Nader, F., & Younossi, Z. M. (2011) · Psychosomatics

Liver Disease Diagnosis and TreatmentHepatitis C virus research

Cited by 147

Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis

Loomba, R., Ratziu, V., Harrison, S. A., Loomba, R., McFarlane, S. C., Tamaki, N., Ratziu, V., Abdelmalek, M. F., Rinella, M. E., Anstee, Q. M., et al. (2022) · Gastroenterology

Liver Disease Diagnosis and TreatmentStatistical Methods in Clinical Trials

Cited by 127

The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis

Younossi, Z. M., Anstee, Q. M., Wai-Sun Wong, V., Trauner, M., Lawitz, E. J., Harrison, S. A., Camargo, M., Kersey, K., Subramanian, G. M., Myers, R. P., et al. (2021) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 118

A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease

Younossi, Z. M., Ong, J. P., Takahashi, H., Yilmaz, Y., Eguc`hi, Y., El Kassas, M., Buti, M., Diago, M., Zheng, M.-H., Fan, J.-G., et al. (2022) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 115

Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States

Golabi, P., Paik, J. M., Kumar, A., Al Shabeeb, R., Eberly, K. E., Cusi, K., GunduRao, N., & Younossi, Z. M. (2023) · Metabolism

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 113

Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis

Loomba, R., Huang, D. Q., Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Ding, D., Ma, L., Jia, C., Billin, A., et al. (2023) · Gut

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 110

Association of chronic liver disease with depression: A population-based study

Lee, K., Otgonsuren, M., Younoszai, Z., Mir, H. M., & Younossi, Z. M. (2013) · Psychosomatics

Hepatitis C virus researchMental Health Treatment and Access

Cited by 104

Physical activity, measured objectively, is associated with lower mortality in patients with nonalcoholic fatty liver disease

Kim, D., Murag, S., Cholankeril, G., Cheung, A., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2021) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentPhysical Activity and Health

Cited by 86

Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis

Sayiner, M., Otgonsuren, M., Cable, R., Younossi, I., Afendy, M., Golabi, P., Henry, L., & Younossi, Z. M. (2017) · Journal of Clinical Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 76

Implementation of a liver health check in people with type 2 diabetes

Abeysekera, K. W. M., Valenti, L., Younossi, Z., Dillon, J. F., Allen, A. M., Noureddin, M., Rinella, M. E., Tacke, F., Francque, S., Ginès, P., et al. (2024) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 63

Vigorous physical activity provides protection against all‐cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD)

Henry, A., Paik, J. M., Austin, P., Eberly, K. E., Golabi, P., Younossi, I., Henry, L., Gerber, L., & Younossi, Z. M. (2023) · Alimentary Pharmacology & Therapeutics

Liver Disease Diagnosis and TreatmentPhysical Activity and Health

Cited by 61